A group of new and existing backers have provided cash to Galecto, based on research from the universities of Lund and Edinburgh.
Backed by Shanghai Fudan University previously, Virogin Biotech will invest the series C proceeds in its clinical drug programmes and securing industry partnerships.
Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer, which builds on work at Amsterdam UMC.
CMU's warehouse vehicle manufacturer Seegrid has more than doubled its latest round to $52m, building on an initial $25m from G2VP six months ago.
Graphite Bio's first drug program will target sickle cell anaemia based on innovations in DNA editing from Stanford University.
Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.